Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Overview

Journal Clin Epidemiol

Publisher Dove Medical Press

Specialty Public Health

Date 2022 Jan 10

PMID 35002327

Authors

Alejandro Arana

Anton Pottegard

Josephina G Kuiper

Helen Booth

Johan Reutfors

Brian Calingaert

Lars Christian Lund

Elizabeth Crellin

Marcus Schmitt-Egenolf

James A Kaye

Karin Gembert

Kenneth J Rothman

Helle Kieler

Daniel Dedman

Eline Houben

Lia Gutierrez

Jesper Hallas

Susana Perez-Gutthann

Affiliations

Soon will be listed here.

Abstract

Purpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma associated with topical TCI use in adults and children, separately.

Patients And Methods: A cohort study in Denmark, Sweden, UK, and the Netherlands was conducted. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated for nonmelanoma skin cancer (NMSC), melanoma, cutaneous T-cell lymphoma (CTCL), non-Hodgkin lymphoma (NHL) excluding CTCL, and Hodgkin lymphoma (HL) in new users of TCIs versus users of moderate/high-potency topical corticosteroids.

Results: The study included 126,908/61,841 adults and 32,605/27,961 children initiating treatment with tacrolimus/pimecrolimus, respectively. Follow-up was ≥10 years for 19% of adults and 32% of children. Incidence rate ratios and (95% confidence intervals) for tacrolimus versus corticosteroid users in adults were <1 for melanoma, non-Hodgkin lymphoma, and Hodgkin lymphoma; and 1.80 (1.25-2.58) for cutaneous T-cell lymphoma. For pimecrolimus, IRRs in adults were <1 for non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and Hodgkin's lymphoma; and 1.21 (1.03-1.41) for melanoma; and 1.28 (1.20-1.35) for nonmelanoma skin cancer. In children, results were inconclusive due to few events. In adults, incidence rate ratios ≥5 years after first topical calcineurin inhibitor exposure were not higher than in overall analyses.

Conclusion: Overall, we found little evidence associating use of topical calcineurin inhibitors with skin cancer and lymphoma; confounding by indication, surveillance bias, and reverse causation may have influenced these results. Even if causal, the public health impact of these excess risks would be low and confined to the first years of exposure.

Citing Articles

Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study.

Yang H, Li P, Shu H, Qian H, Chen J, Wang S Paediatr Drugs. 2025; .

PMID: 39873962 DOI: 10.1007/s40272-025-00682-w.

Recurrence rate of corneal squamous cell carcinoma in dogs undergoing superficial keratectomy surgery.

Mather H, Stanley R Open Vet J. 2024; 14(11):3063-3073.

PMID: 39737039 PMC: 11682761. DOI: 10.5455/OVJ.2024.v14.i11.35.

Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis.

Ali S, Ion A, Orzan O, Balaceanu-Gurau B Pharmaceutics. 2024; 16(11).

PMID: 39598548 PMC: 11597258. DOI: 10.3390/pharmaceutics16111425.

Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome.

Oland C, Ranch L, Skaaby T, Delvin T, Jakobsen H, Pipper C PLoS One. 2024; 19(7):e0304145.

PMID: 38995938 PMC: 11244844. DOI: 10.1371/journal.pone.0304145.

Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research.

Wang S, Pottegard A Am J Epidemiol. 2024; 193(11):1625-1631.

PMID: 38794897 PMC: 11538565. DOI: 10.1093/aje/kwae087.

References

Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger R, Fernandez-Vidaurre C . Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009; 219(1):7-21. DOI: 10.1159/000209289. View

Brookhart M, Schneeweiss S, Rothman K, Glynn R, Avorn J, Sturmer T . Variable selection for propensity score models. Am J Epidemiol. 2006; 163(12):1149-56. PMC: 1513192. DOI: 10.1093/aje/kwj149. View

Berg D, Otley C . Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002; 47(1):1-17; quiz 18-20. DOI: 10.1067/mjd.2002.125579. View

Arana A, Wentworth C, Fernandez-Vidaurre C, Schlienger R, Conde E, Arellano F . Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010; 163(5):1036-43. DOI: 10.1111/j.1365-2133.2010.09887.x. View

Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O . Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999; 40(2 Pt 1):177-86. DOI: 10.1016/s0190-9622(99)70185-4. View

Ortqvist A, Lundholm C, Wettermark B, Ludvigsson J, Ye W, Almqvist C . Validation of asthma and eczema in population-based Swedish drug and patient registers. Pharmacoepidemiol Drug Saf. 2013; 22(8):850-60. DOI: 10.1002/pds.3465. View

Tennis P, Gelfand J, Rothman K . Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011; 165(3):465-73. DOI: 10.1111/j.1365-2133.2011.10363.x. View

Castellsague J, Kuiper J, Pottegard A, Berglind I, Dedman D, Gutierrez L . A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018; 10:299-310. PMC: 5856050. DOI: 10.2147/CLEP.S146442. View

Zwald F, Brown M . Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011; 65(2):253-261. DOI: 10.1016/j.jaad.2010.11.062. View

10.

Arellano F, Wentworth C, Arana A, Fernandez C, Paul C . Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2006; 127(4):808-16. DOI: 10.1038/sj.jid.5700622. View

11.

Asgari M, Tsai A, Avalos L, Sokil M, Quesenberry Jr C . Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. JAMA Dermatol. 2020; 156(10):1066-1073. PMC: 7557510. DOI: 10.1001/jamadermatol.2020.2240. View

12.

Sturmer T, Wyss R, Glynn R, Brookhart M . Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014; 275(6):570-80. PMC: 4037382. DOI: 10.1111/joim.12197. View

13.

Mittal A, Colegio O . Skin Cancers in Organ Transplant Recipients. Am J Transplant. 2017; 17(10):2509-2530. DOI: 10.1111/ajt.14382. View

14.

Margolis D, Abuabara K, Hoffstad O, Wan J, Raimondo D, Bilker W . Association Between Malignancy and Topical Use of Pimecrolimus. JAMA Dermatol. 2015; 151(6):594-9. PMC: 4465068. DOI: 10.1001/jamadermatol.2014.4305. View

15.

Hartevelt M, Bavinck J, Kootte A, Vermeer B, Vandenbroucke J . Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990; 49(3):506-9. DOI: 10.1097/00007890-199003000-00006. View

16.

Hui R, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009; 43(12):1956-63. DOI: 10.1345/aph.1M278. View

17.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. View

18.

Paller A, Folster-Holst R, Chen S, Diepgen T, Elmets C, Margolis D . No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020; 83(2):375-381. DOI: 10.1016/j.jaad.2020.03.075. View

19.

Lam M, Zhu J, Tadrous M, Drucker A . Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021; 157(5):549-558. PMC: 8014232. DOI: 10.1001/jamadermatol.2021.0345. View